Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers

Mylan's plan to provide a generic version of its emergency allergic reaction drug EpiPen may be a good PR move, but it may alienate payers further. It also has spurred new skepticism about the company's pricing practices.